|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Part 4: Technical Advances in PD |
Division of Nephrology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, PR China
Correspondence: P.K.T. Li, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, PR China. philipli{at}cuhk.edu.hk
This article examines the roles of continuous ambulatory peritoneal
dialysis (CAPD) versus automated peritoneal dialysis (APD) as first-line renal
replacement therapy. To date, no high-quality large-scale randomized
controlled studies have compared CAPD with APD as first-line therapy. However,
a discussion on this issue is important so that nephrologists can decide and
patients can have a choice of modality on which to start dialysis, especially
in the context of health care economics. We review the literature and present
Hong Kong as the model of a "CAPD first" policy, an appealing,
cost-effective approach for any country.
An ideal renal replacement therapy should provide optimal survival,
lowest possible risk for comorbidity, highest level of quality of life, and
equally important, acceptable cost to society. When we consider this subject
in the context that all patients should be started on one first-line modality,
the data suggest that a "CAPD first" policy has all these
advantages, with APD probably having the edge only with regard to patient
preference. The present review highlights preservation of residual renal
function, removal and balancing of sodium, incidence of peritonitis,
peritoneal membrane transport status, patient rehabilitation, and financial
issues in demonstrating that a "CAPD first" policy is the model
that should be adopted.
KEY WORDS: Continuous ambulatory peritoneal dialysis; automated peritoneal dialysis; first-line therapy; cost; residual renal function.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |